Redeye updates in Better Collective ahead of Q2-results (due 20 August after market close) where we ...
Redeye updates its view on Genovis' following a Q2 2025 report falling slightly short of our estimat...
The economic environment and end demand has not been very favourable for Aspo.
Redeye comments on Xspray’s out-licensing of certain patents covering the commercialization of a das...
The company’s adjusted EBITDA was EUR 3.1m (pre-announced) in Q2.
Redeye's view of Genovis Q2 report is balanced, sales were largely in line but profitability was sof...
Q2 confirms that Moberg’s Terclara is now the market leader in both Sweden and Norway.
Raute’s EUR 43.8m Q2 top line came in clearly below our estimate, yet the EUR 6.
Marimekko reports its Q2 figures on 14th of August.
Q2 report due on Thursday, 14 August Sales and margin downgrades in Germany weigh on estimates Tradi...
Redeye comments on Alzinova’s announcement of having submitted an IND application and a Fast Track D...
Group net sales was EUR 29.5m in Q2 (Nordea EUR 30.
SRV’s Q2 figures fell short of our estimates for both volumes and profitability.
Redeye comments on q.beyond’s Q2 report showing a slightly more substantial improvement in EBITDA an...
Redeye presents its preview for Paxman’s Q2 2025 report, due on August 20.
